Financials INBIOGEN Co., Ltd.

Equities

A101140

KR7101140002

Business Support Services

End-of-day quote Korea S.E. 06:00:00 2023-03-30 pm EDT 5-day change 1st Jan Change
9,340 KRW -2.30% Intraday chart for INBIOGEN Co., Ltd. -.--% -.--%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 142,062 115,240 253,364 186,337 51,597 93,320
Enterprise Value (EV) 1 121,235 97,078 179,101 176,595 44,082 87,825
P/E ratio 67.5 x 10.1 x -4.81 x 2.26 x -0.47 x -
Yield - - - - - -
Capitalization / Revenue 18.8 x 11.8 x 24.8 x 17.8 x 4.52 x 15 x
EV / Revenue 16 x 9.91 x 17.5 x 16.8 x 3.87 x 14.1 x
EV / EBITDA 86.5 x -68.6 x -37.2 x -25.1 x -9.8 x -17.6 x
EV / FCF 20.6 x 11.4 x -16.6 x -20 x -2.62 x -53.6 x
FCF Yield 4.85% 8.78% -6.04% -4.99% -38.1% -1.87%
Price to Book 5.86 x 1.75 x 3.4 x 1.05 x 1.04 x -
Nbr of stocks (in thousands) 1,450 1,930 2,418 2,617 3,329 9,991
Reference price 2 98,000 59,700 104,800 71,200 15,500 9,340
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 7,566 9,795 10,218 10,481 11,404 6,241
EBITDA 1 1,402 -1,414 -4,817 -7,029 -4,496 -4,995
EBIT 1 1,367 -1,669 -5,261 -8,146 -5,934 -6,219
Operating Margin 18.07% -17.04% -51.49% -77.73% -52.04% -99.65%
Earnings before Tax (EBT) 1 1,477 13,124 -45,218 111,064 -136,640 19,372
Net income 1 1,664 13,124 -45,078 94,125 -119,687 18,857
Net margin 21.99% 133.98% -441.17% 898.07% -1,049.54% 302.16%
EPS 2 1,452 5,940 -21,809 31,499 -33,008 -
Free Cash Flow 1 5,876 8,523 -10,815 -8,817 -16,810 -1,639
FCF margin 77.66% 87.02% -105.85% -84.12% -147.41% -26.27%
FCF Conversion (EBITDA) 419.18% - - - - -
FCF Conversion (Net income) 353.11% 64.95% - - - -
Dividend per Share - - - - - -
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 20,827 18,163 74,263 9,742 7,515 5,496
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 5,876 8,523 -10,815 -8,817 -16,810 -1,639
ROE (net income / shareholders' equity) 9.6% 29.4% -62.7% 61.5% -65.6% 13.6%
ROA (Net income/ Total Assets) 4.53% -1.81% -3.5% -2.74% -1.78% -2.65%
Assets 1 36,719 -724,918 1,287,342 -3,432,586 6,716,831 -711,050
Book Value Per Share 2 16,715 34,189 30,850 68,023 14,935 -
Cash Flow per Share 2 442.0 4,166 3,609 8,846 1,329 -
Capex - 288 428 2,360 131 26
Capex / Sales - 2.94% 4.19% 22.52% 1.15% 0.42%
Announcement Date 3/1/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. A101140 Stock
  4. Financials INBIOGEN Co., Ltd.